Adoptive Cell & CAR T-Cell Therapies
With over 80 unique hematological malignancy cell lines, such as the CD19+ Raji-Luc lymphoma model, the MV-4-11-Luc-mCh-Puro leukemia model, and the MM.1S-Luc-Neo multiple myeloma model, we lead the industry with market-relevant models for your studies. 我们还拥有规模不断扩展、在NSG小鼠中经过验证的实体瘤模型,以支持该领域实现对实体瘤适应症采用过继细胞疗法(ACT)的批准。